Alteplase
- Generic Name
- Alteplase
- Brand Names
- Activase, Cathflo, Cathflo Activase
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 105857-23-6
- Unique Ingredient Identifier
- 1RXS4UE564
- Background
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...
- Indication
Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...
- Associated Conditions
- Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
- Associated Therapies
- -
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
- Conditions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2006-08-01
- Lead Sponsor
- O'Brien, Jeana D., MD, FACP, FCCP
- Target Recruit Count
- 75
- Registration Number
- NCT00103766
- Locations
- 🇺🇸
Scott and White Memorial Hospital & Clinic, Temple, Texas, United States
Thrombolysis in Myocardial Infarction (TIMI)
- Conditions
Myocardial Infarction Triage and Intervention Project (MITI)
- Conditions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- University of Washington
- Registration Number
- NCT00000468
Thrombolysis in Myocardial Ischemia Trial (TIMI III)
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.